



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/591,923-Conf. #5393		
		Filing Date	September 5, 2006		
		First Named Inventor	Daniel J. Rader		
		Art Unit	1614		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	5	Attorney Docket Number	AGP-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/K.W./	A1*	US-20020035064-A1	03-21-2002	Robl et al.	
	A2*	US-20020045271-A1	04-18-2002	Hussain et al.	
	A3*	US-20030069221-A1	04-10-2003	Kosoglou et al.	
	A4*	US-20030109543-A1	06-12-2003	Ogletree	
	A5*	US-20030162788-A1	08-28-2003	Thomas et al.	
	A6*	US-20030187053-A1	04-13-2004	Bertinato et al.	
	A7*	US-20040014748-A1	01-22-2004	Grutzmann et al.	
	A8*	US-20040058908-A1	03-25-2004	Keller et al.	
	A9*	US-20050075367-A1	04-07-2005	Hagiwara et al.	
	A10*	US-20050090426-A1	04-28-2005	Blumberg	
	A11*	US-20050101561-A1	05-12-2005	Tunac	
	A12*	US-20060069161-A1	03-30-2006	Lee et al.	
	A13*	US-20060135460-A1	06-22-2006	Widder et al.	
	A14*	US-20060153913-A1	07-13-2006	Yamane et al.	
	A15*	US-20060205726-A1	09-14-2006	Hagiwara et al.	
	A16*	US-20060211020-A1	09-21-2006	Farrer et al.	
	A17*	US-20060211762-A1	09-21-2006	Rongen et al.	
	A18*	US-20060270655-A1	11-30-2006	Swick et al.	
	A19*	US-20070088089-A1	04-19-2007	Wisler	
	A20*	US-20070093468-A1	04-26-2007	Wisler	
	A21*	US-20070093527-A1	04-26-2007	Wisler	
	A22*	US-3,983,140	09-28-1976	Endo et al.	
	A23*	US-4,231,938	11-04-1980	Monaghan et al.	
	A24*	US-4,346,227	08-24-1982	Terahara et al.	
	A25*	US-4,448,784	05-15-1984	Glamkowski et al.	
	A26*	US-4,450,171	05-22-1984	Hoffman et al.	
	A27*	US-4,499,289	02-12-1985	Baran et al.	
	A28*	US-4,613,610	09-23-1986	Wareing	
	A29*	US-4,647,576	03-03-1987	Hoefle et al.	
	A30*	US-4,686,237	08-11-1987	Anderson	
	A31*	US-4,871,721	10-03-1989	Biller	
	A32*	US-4,924,024	05-08-1990	Biller	
	A33*	US-5,117,080	05-26-1992	Lee et al.	
	A34*	US-5,595,872	01-21-1997	Wetterau, II et al.	
	A35*	US-5,684,014	11-04-1997	Muller et al.	
	A36*	US-5,712,279	01-27-1998	Biller et al.	
	A37*	US-5,712,396	01-27-1998	Magnin et al.	
	A38*	US-5,739,135	04-14-1998	Biller et al.	
	A39*	US-5,760,246	06-02-1998	Biller et al.	
	A40*	US-5,786,361	07-28-1998	Muller et al.	
	A41*	US-5,789,197	08-04-1998	Wetterau, II et al.	
	A42*	US-5,811,429	09-22-1998	Connell et al.	
	A43*	US-5,827,875	10-27-1998	Dickson, Jr. et al.	
	A44*	US-5,883,109	03-16-1999	Gregg et al.	
	A45*	US-5,885,983	03-23-1999	Biller et al.	
/K.W./	A46*	US-5,952,498	09-14-1999	Lenfers et al.	
	A47*	US-5,990,110	11-23-1999	Firestone	

Examiner Signature	/Kevin Weddington/	Date Considered	10/08/2009
--------------------	--------------------	-----------------	------------

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/591,923-Conf. #5393
				Filing Date	September 5, 2006
				First Named Inventor	Daniel J. Rader
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	5	Attorney Docket Number	AGP-002

/K.W./	A48*	US-6,034,115	03-07-2000	Connell et al.	
	A49*	US-6,057,339	05-02-2000	Gregg	
	A50*	US-6,066,650	05-23-2000	Biller et al.	
	A51*	US-6,066,653	05-23-2000	Gregg et al.	
	A52*	US-6,114,341	09-05-2000	Muller et al.	
	A53*	US-6,245,775	06-12-2001	Muller et al.	
	A54*	US-6,265,431	07-24-2001	Muller et al.	
	A55*	US-6,297,233	10-02-2001	Stein et al.	
	A56*	US-6,344,450	02-05-2002	Bisacchi et al.	
	A57*	US-6,479,503-A1	11-12-2002	Muller et al.	
	A58*	US-6,492,365	12-10-2002	Wetterau, II et al.	
	A59*	US-6,498,156-A1	12-24-2002	Glombik et al.	
	A60*	US-6,620,821-A1	09-16-2003	Robl	
	A61*	US-6,627,636	09/20/2003	Robl	
	A62*	US-6,720,351-A1	04-13-2004	Berlino et al.	
	A63*	US-6,774,236	08-10-2004	Lenfers et al.	
	A64*	US-6,812,345-A1	11-02-2004	Robl et al.	
	A65*	US-6,846,836-A1	01-25-2005	Hamann et al.	
	A66*	US-6,858,622-A1	02-22-2005	Muller et al.	
	A67*	US-6,875,782-A1	04-05-2005	Cheng et al.	
	A68*	US-6,916,809-A1	07-12-2005	Chen et al.	
	A69*	US-6,916,813-A1	07-12-2005	Atwal et al.	
	A70*	US-6,949,572-A1	09-27-2005	Berlino et al.	
	A71*	US-6,979,692-A1	12-27-2005	Berlino et al.	
/K.W./	A72*	US-7,053,080-A1	05-30-2006	Davis et al.	
	A73*	US-7,056,906-A1	06-06-2006	Strony	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T*
		Country Code*	Number* Kind Code* (if known)				
/K.W./	B1	EP	0142146	05-22-1985	Merck & Co Inc		
	B2	EP	0221025	05-06-1987	Sandoz Ag et al.		
	B3	EP	0325130	07-26-1989	Bayer Ag		✓
	B4	EP	0705831	04-10-1996	Bayer Ag		✓
	B5	EP	0779276	06-18-1997	Bayer Ag		✓
	B6	EP	0779279	06-18-1997	Bayer Ag		✓
	B7	EP	0799828	10-08-1997	Bayer Ag		✓
	B8	EP	0802198	10-22-1997	Bayer Ag		✓
	B9	EP	1 181 954 A	02-27-2002	Pfizer		
	B10	EP	1099442	05-16-2001	Pfizer Prod Inc		
	B11	CA	2091102	09-07-1993	Squibb & Sons Inc		
	B12	GB	2205637	12-21-1988	Squibb & Sons Inc		
	B13	FR	2596393	10-02-1987	Sanofi Sa		✓
	B14	AU	727895	07-23-1998	Bristol Myers Squibb Co		
	B15	CA	2291471	06-04-2000	Pfizer Prod Inc		
	B16	CA	2325201	05-10-2001	Pfizer Prod Inc		
/K.W./	B17	DE	19951022	04-26-2001	Bayer Ag		✓
	B18	JP	2002-220345	08-09-2002	Sumitomo Pharma		✓

Examiner Signature	/Kevin Weddington/	Date Considered	10/08/2009
--------------------	--------------------	-----------------	------------

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/591,923-Conf. #5393
		Filing Date	September 5, 2006
		First Named Inventor	Daniel J. Rader
		Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	AGP-002
Sheet	3	of	5

/K.W./	B19	WO-00/038725	07-06-2000	Searle & Co et al.		
	B20	WO-01/008679	02-08-2001	Verkade Hendrik Jan		
	B21	WO-04/028544	04-08-2004	Novo Nordisk A/S		
	B22	WO-04/110368	12-23-2004	Merck & Co., Inc.		
	B23	WO-04/110375	12-23-2004	Merck & Co., Inc.		
	B24	WO-05/000217	01-06-2005	Merck & Co., Inc.		
	B25	WO-05/051382	11-25-2004	Yamanouchi Pharmaceutical		√
	B26	WO-05/072740	08-11-2005	Japan Tobacco Inc.		
	B27	WO-05/084666	09-15-2005	Abeille Pharmaceuticals		
	B28	WO-05/094864	10-13-2005	Max-Planck Gesellschaft Zur		
	B29	WO-05/097131	10-25-2005	Janssen Pharmaceutica NV		
	B30	WO-06/046623	05-04-2006	Japan Tobacco Inc.		√
	B31	WO-06/062748	06-15-2006	Reliant Pharmaceuticals, Inc.		
	B32	WO-06/063128	06-15-2006	Sytera, Inc.		
	B33	WO-06/108666	10-19-2006	Proteosys AG		
	B34	WO-06/111238	10-26-2006	Merck Patent GMBH		
	B35	WO-07/047880	04-26-2007	Aegerion Pharmaceuticals		
	B36	WO-05/087234	09-22-2005	Rader		
	B37	WO-86/003488	06-19-1986	Sandoz Ag		
	B38	WO-86/007054	12-04-1986	Sandoz Ag et al.		
	B39	WO-96/026205	08-29-1996	Squibb Bristol Myers Co		
	B40	WO-96/040640	12-19-1996	Pfizer et al.		
	B41	WO-97/041111	11-06-1997	Pfizer et al.		
	B42	WO-98/003069	01-29-1998	Squibb Bristol Myers Co		
	B43	WO-98/003174	01-29-1998	Squibb Bristol Myers Co		
	B44	WO-98/023593	06-04-1998	Pfizer et al.		
	B45	WO-98/027979	07-02-1998	Squibb Bristol Myers Co		
	B46	WO-98/031225	07-23-1998	Squibb Bristol Myers Co		
↓	B47	WO-98/031366	07-23-1998	Squibb Bristol Myers Co		
	B48	WO-98/031367	07-23-1998	Squibb Bristol Myers Co		
	B49	WO-98/050028	11-12-1998	Squibb Bristol Myers Co		
/K.W./	B50	WO-07/047724	04-26-2007	Wisler		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(e)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kevin Weddington/	Date Considered	10/08/2009
--------------------	--------------------	-----------------	------------

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/591,923-Conf. #5393
		Filing Date	September 5, 2006
		First Named Inventor	Daniel J. Rader
		Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	AGP-002
Sheet	4	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
K.W./	C1	Atzel, A., et al., "Mechanism of Microsomal Triglyceride Transfer Protein Catalyzed Lipid Transport", <i>Biochemistry</i> (1993), 32, 10444-10450.	
	C2	Bakillah A. et al., "Decreased Secretion of ApoB follows inhibition of ApoB-MTP Binding by a Novel Antagonist", <i>Biochemistry (Mosc)</i> , (2000) 39(16):4892-4899.	
	C3	Barclay, "Hyperlipidemia", <i>NMT Briefs</i> , 2003.	
	C4	Bayes, M., et al., "Gateways to Clinical Trials", <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 24(1):2002, 37-55.	
	C5	Bays et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", <i>Expert Opin Pharmacother</i> , 2003 Nov;4(11):1901-38.	
	C6	Billar et al., "Isoprenoid (Phosphinylmethyl) Phosphonates as Inhibitors of Squalene synthetase", <i>J. Med. Chem.</i> , 31 (10):1988, 1669-71.	
	C7	Bruckert, "New Lipid-Modifying Therapies", <i>Expert Opin. Investig. Drugs</i> , (2003)12(3):325-35.	
	C8	Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).	
	C9	Chang et al., "Microsomal Triglyceride Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", <i>Current Opinion in Drug Discovery & Development</i> , (2002) 5(4):562-70.	
	C10	Corey and Volante, <i>J. Am. Chem. Soc.</i> , (1976) 98:1291-93.	
	C11	de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", <i>J. Med. Chem.</i> , (1977) 20:243-49.	
	C12	Earl et al., "Ezetimibe", <i>Nature Reviews</i> , 2003, 2:97-98.	
	C13	Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", <i>Drugs</i> , 2004; 64 (11): pp. 1181-1196	
	C14	Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel III Report. Publication number 01-3095, I-1-X-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.	
	C15	Farrell, "Drugs and Steatohepatitis", <i>Semin Liver Dis</i> , (2002) 22(2):185-194.	
	C16	Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", <i>Circulation</i> , (2002) 105 (21):2469-75.	
	C17	International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).	
	C18	International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).	
	C19	International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).	
	C20	International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).	
	C21	International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).	
	C22	Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", <i>Proc Natl Acad Sci U S A</i> , (1996) 93(21):11991-11995.	
	C23	Kastelein J., "What Future for Combination Therapies", <i>Int J. Clin Pract. Suppl.</i> 2003 March; (134): pp. 45-50	
	C24	Kirkpatrick et al., "Market indicators", <i>Nature</i> , 2003, 2:98.	
	C25	Liao et al., "Blocking Microsomal Triglyceride Transfer Protein Interferes with apoB Secretion	

Examiner Signature	/Kevin Weddington/	Date Considered	10/08/2009
--------------------	--------------------	-----------------	------------

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/591,923-Conf. #5393
				Filing Date	September 5, 2006
				First Named Inventor	Daniel J. Rader
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	5	of	5	Attorney Docket Number	AGP-002

/K.W./		Without Causing Retention or Stress in the ER", Journal of Lipid Research, (2003) 44(5):978.	
	C26	McClard et al., J.A.C.S., (1987) 109:5544.	
	C27	Ritter et al., "Heterocyclic Ring Scaffolds as Small-Molecule Cholesterol Absorption Inhibitors", Org. Biomol. Chem., 2005, 3:3514-3523.	
	C28	Robl et al., "A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors", Journal of Medicinal Chemistry, 2001, 44(6):851-856.	
	C29	Shiomi et al., "MTP Inhibitor Decreases Plasma Cholesterol Levels in LDL Receptor-Deficient WHHL Rabbits by Lowering the VLDL Secretion", Euro. Journal of Pharma. 2001, 431:127-131.	
	C30	Sorbara, L.A., et al., Implitapide "Hypolipidemic Treatment of Atherosclerosis MTP Inhibitor ApoB Secretion Inhibitor", Drugs of the Future, (2000) 25(11):1138-1144.	
	C31	Subhop et al., "Cholesterol Absorption Inhibitors For the Treatment of Hypercholesterolaemia", Drugs, 2002, 62(16):2333-2347.	
	C32	Thomas et al., "Alleviation of MTP Inhibitor-Induced Hepatic Steatosis in Hyperlipidemic fa/fa Rats by Fenofibrate", Dept. of Metabolic Diseases and Dept. of Chemical Research, Boehringer Ingelheim Pharma GmbH & Co. KG. (2005)	
	C33	Wetterau et al., "An MTP Inhibitor that Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits", Science, (1998) 282(5389):751-754.	
↓	C34	Wetterau et al., "Microsomal Triglyceride Transfer Protein", Biochimica Biophysica Acta, (1997) 1345(2):136-150.	
/K.W./	C35	Wierzbicki A.S., "New Lipid-Lowering Agents", Expert Opinion on Emerging Drugs, Ashley Publications, GB, 8 (2):2003, 365-376.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

LIBC/3095947v1

Examiner Signature	/Kevin Weddington/	Date Considered	10/08/2009
-----------------------	--------------------	--------------------	------------